Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Trouts hiding today.
Been silent here for weeks trout not just today so your theory is floored……again
Happy new year all
Oh trout lol
Trout
You really are obsessed with Dukemount Capital🤣 anyone else not agree ??
Still here all, watching and waiting……more waiting but at least an update even though it was forced.
This is on its way to 30p as it should be.
(mrkcap ÂŁ13m) fit into this camp, reflecting positive fundamentals and continued strong execution.
In fact today, Verici announced that a leading US medical publication, The American Journal of Transplantation, had confirmed that its flagship post-surgery test Tutivia "demonstrates strong performance in the assessment of risk of acute rejection following kidney transplant". This is especially important for doctors during the first few weeks post-graft, when patient management can be complex and other biomarkers are contraindicated or less informative.
This milestone represents not only another major endorsement of the quality of
VRCI
’s medical science, but also a further crucial step in the commercialisation of Tutivia. As the company builds industry trust and recognition, it continues to gain local coverage determination (LCD) for Medicare reimbursement - which should in turn increase usage and transplant centre adoption.
Dr. Lorenzo Gallon, Chair of Scientific Advisory Board of Verici Dx commented: "I am delighted that the data from our pivotal validation study for Tutivia has been published in such a high-impact and prestigious journal as The American Journal of Transplantation."
CMO Dr Michael Donovan, DMD, added: "This publication further validates the benefits of the test for kidney transplant patients and their clinicians, and demonstrates the comprehensive design of the study to reflect the full clinical continuum."
COO Patti Connolly, concluded: "We are already seeing growing clinical interest, and as this publication is key in the application for LCD coverage, we anticipate an accelerated adoption of Tutivia within the medical community, marking a significant step forward in enhancing diagnostic accuracy and post-transplant patient care."
Finally regarding financials, Singer Capital Markets are anticipating revenues to jump from $0.3m in FY23 to $8.6m next year while delivering an adjusted EBITDA of $0.1m in 2024 and closing Dec'23 with net cash of $0.1m. They have a BUY rating with a 30p target price.
VRCI
shares jumped 13% on today's announcement.
Trout is here because he doesn’t want it to succeed.
He will be wrong.
That’s correct Radika, they will dilute the shares.
BTC $42k
Trout
You just don’t get it, do you!!!
Ha yes you can but it just shows what a sad individual you actually are…..I’m confident you will be selling the small trades off 🤣
Trout
Your not invested, why do you care 🤣🤣
Radika. The rise is still there, someone is just trying to make it look worse than it is.
Corruption
Great start to the week.
Negative Negative Negative Negative.
What a way to be.
God help you.
Aim iss very obvious it’s a buy 👍